A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib
| Autor: | Miho Maeda, Miho Yamanishi, Chitose Ogawa, Tomoko Sonoda, Akiko Miyagi Maeshima, Ayumu Arakawa, Nami Shirakawa, Yoshimasa Saito, Sae Ishimaru, Tadashi Kumamoto, Yuki Aoki, Masanaka Sugiyama |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine MAPK/ERK pathway medicine.medical_specialty Adolescent MAP Kinase Signaling System Pyridones MAP Kinase Kinase 1 Pyrimidinones Histiocytic sarcoma 03 medical and health sciences 0302 clinical medicine Refractory Recurrence Internal medicine medicine Humans Neoplasm Protein Kinase Inhibitors Rosai–Dorfman disease Trametinib Hematology business.industry MEK inhibitor medicine.disease Treatment Outcome 030104 developmental biology 030220 oncology & carcinogenesis Cancer research Histiocytic Sarcoma business |
| Zdroj: | International Journal of Hematology. 109:228-232 |
| ISSN: | 1865-3774 0925-5710 |
| Popis: | Histiocytic sarcoma in advanced clinical stages is typically an aggressive neoplasm, with poor response to conventional chemotherapy. An 18-year-old male with refractory histiocytic sarcoma that had transformed from Rosai-Dorfman disease was admitted to our hospital. A pathogenic variant of MAP2K1 was detected by next-generation sequencing of tumor specimens. Affected regions showed excellent responses to the MEK inhibitor trametinib. It has been reported that RAS/MEK/ERK pathway is activated in many cases of histiocytic sarcoma. MEK inhibition may represent a useful treatment option in histiocytic sarcoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink